NephroPlus

+40%

est. 2Y upside i

HealthcareSeries D+

Rank

#1164

Sector

Healthcare Services

Est. Liquidity

~0Y

Data Quality

Data: Medium

NephroPlus offers an expected 2-year upside of ~40% despite a stale pre-IPO valuation of $240M and a large $205M preference overhang.

Last updated: July 19, 2026

Bull (25%)+80%

Exit multiple expands to 4.0x due to IPO window and category leadership, yielding $738M exit; after 20% dilution, upside is 80%.

Base (55%)+73%

Exit multiple converges to 2.5x, in line with comps, yielding $461M exit; after 20% dilution, upside is 72.5%.

Bear (20%)-100%

Exit multiple compresses to 1.0x, yielding $185M exit below $205M preference overhang; common stock is wiped out.

Est. time to liquidity~0.0 years

Preference Stack Risk

severe

Funding Intensity

8560%

Total funding of $205M represents 85.6% of the stale entry valuation, creating severe preference overhang.

Dilution Risk

moderate

Further capital raises are possible to fund acquisitions and expansion, likely resulting in ~20% dilution over 2 years.

Secondary Liquidity

active

Company is public (IPO Dec 2025), providing immediate liquidity for shares.

Other — 19 roles

Last updated: September 6, 2026

Questions to Ask at the Interview

Strategic questions based on NephroPlus's data — designed to show you've done your homework.

1
“How does NephroPlus’s cost advantage and scale protect against competition from large hospital chains?”
2
“What is the company’s strategy for expanding public-private partnerships and international operations?”
3
“Given the large preference stack, how do you evaluate the risk of dilution and the timeline for common equity to realize value?”

Our model estimates +40% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.